Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Health Information Technology and Healthcare Information System01:30

Health Information Technology and Healthcare Information System

883
Health Information Technology (HIT)
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:
883
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

358
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
358
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

310
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
310
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

1.2K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
1.2K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.6K
Substance Use Disorders Affecting Sleep01:24

Substance Use Disorders Affecting Sleep

201
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
201

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methodological innovations to advance substance use disorder research: Proceedings of a NIDA workshop on target trial emulation and translational testing of digital health tools.

Journal of substance use and addiction treatment·2026
Same author

Engaging Rural Practitioners and Community Collaborators in Substance Use Disorder Needs Assessments: Recruitment Approaches Across 4 States.

Journal of public health management and practice : JPHMP·2026
Same author

Temporal Relationships between Smartphone Application Use and Online Substance Procurement in U.S. Youth.

medRxiv : the preprint server for health sciences·2026
Same author

"We need to keep in mind that battle fatigue": A commentary on moral injury among substance use treatment and community service providers.

Journal of substance use and addiction treatment·2026
Same author

The community representative council of the National Drug Abuse Treatment Clinical Trials Network: Co-design and early impact.

Journal of substance use and addiction treatment·2026
Same author

Implementing pragmatic clinical trials in rural settings: Challenges, solutions and lessons learned.

Journal of substance use and addiction treatment·2026

Related Experiment Video

Updated: Aug 1, 2025

Use of the Operant Orofacial Pain Assessment Device OPAD to Measure Changes in Nociceptive Behavior
12:20

Use of the Operant Orofacial Pain Assessment Device OPAD to Measure Changes in Nociceptive Behavior

Published on: June 10, 2013

21.2K

Augmenting project ECHO for opioid use disorder with data-informed quality improvement.

Owen B Murray1, Marcy Doyle2, Bethany M McLeman3

  • 1Northeast Node of the Clinical Trials Network, Center for Technology and Behavioral Health, Geisel School of Medicine at Dartmouth College, 46 Centerra Parkway, Suite 315, NH, 03766, Lebanon, USA. Owen.B.Murray@dartmouth.edu.

Addiction Science & Clinical Practice
|April 27, 2023
PubMed
Summary
This summary is machine-generated.

Training clinics to collect performance data and initiate quality improvement (QI) alongside buprenorphine providers in Project ECHO showed feasibility. Data-informed QI initiatives were completed, suggesting potential for improved clinical best practices in opioid use disorder treatment.

Keywords:
BuprenorphineECHOMedications for opioid use disorderPrimary careQuality improvement

More Related Videos

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

842
Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.3K

Related Experiment Videos

Last Updated: Aug 1, 2025

Use of the Operant Orofacial Pain Assessment Device OPAD to Measure Changes in Nociceptive Behavior
12:20

Use of the Operant Orofacial Pain Assessment Device OPAD to Measure Changes in Nociceptive Behavior

Published on: June 10, 2013

21.2K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

842
Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.3K

Area of Science:

  • Medical Research
  • Public Health
  • Addiction Medicine

Background:

  • Opioid overdose fatalities remain a significant public health crisis, particularly in rural areas.
  • Medications for Opioid Use Disorder (MOUD) are effective, but access barriers persist, especially for methadone in rural settings.
  • Buprenorphine offers increased accessibility in rural areas, yet prescribing barriers like inadequate training and expert access remain.

Purpose of the Study:

  • To explore the feasibility of training clinics to collect performance data for quality improvement (QI).
  • To assess the initiation of QI initiatives alongside participation in a Project ECHO virtual collaborative for buprenorphine providers.
  • To address barriers in buprenorphine prescribing through data collection and QI.

Main Methods:

  • Eighteen New Hampshire clinics in a Project ECHO were offered supplemental training on performance data collection for QI.
  • Feasibility was assessed via participation in training, data submission, and QI initiatives.
  • An end-of-project survey evaluated clinic staff perceptions of usefulness and acceptability.

Main Results:

  • Five clinics (four serving rural areas) engaged, meeting criteria for training, data submission, and QI completion.
  • Clinic staff found the training and data collection useful but faced barriers like staff time and EHR documentation standardization.
  • Despite inconsistent data collection, clinics successfully completed data-informed QI initiatives.

Conclusions:

  • Training clinics in performance monitoring and data-driven QI shows potential for improving clinical best practices in buprenorphine prescribing.
  • Smaller-scale data collection appears more attainable for clinics facing resource constraints.
  • This approach can help overcome barriers to effective opioid use disorder treatment in diverse settings.